A phase I study of indoximod in patients with advanced malignancies

PURPOSE: Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Secondary endpoints included response rates, pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Hatem H., Minton, Susan E., Han, Hyo Sook, Ismail-Khan, Roohi, Neuger, Anthony, Khambati, Fatema, Noyes, David, Lush, Richard, Chiappori, Alberto A., Roberts, John D., Link, Charles, Vahanian, Nicholas N., Mautino, Mario, Streicher, Howard, Sullivan, Daniel M., Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008412/
https://www.ncbi.nlm.nih.gov/pubmed/27008709
http://dx.doi.org/10.18632/oncotarget.8216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008412/
https://www.ncbi.nlm.nih.gov/pubmed/27008709
http://dx.doi.org/10.18632/oncotarget.8216

Ejemplares similares